News

MBF Bioscience Announces the Acquisition of Vidrio Technologies

MBF Bioscience, a leading provider of bioscience image analysis tools, announced that it has completed the acquisition of Vidrio Technologies. Terms of the transaction were not disclosed.

Based in Ashburn, VA, Vidrio is a fast-growing provider of software and hardware components for laser scanning and two photon microscopes.

“Vidrio Technologies builds widely loved tools for researchers who utilize two photon and laser scanning microscopes to answer some of the toughest questions in biology,” says MBF Bioscience Founder and President Jack Glaser. “They have assembled a truly special team of engineers and I am thrilled that MBF will have the opportunity to be a part of the continued development, release, and support of Vidrio’s impressive products.”

“The team at Vidrio couldn’t be more excited to be joining forces with MBF,” says Vidrio Technologies CEO Bruce Kimmel. “We have grown rapidly in recent years and MBF’s large development team will be a great resource for us as we continue to invest in the development of industry-leading tools for bioscience researchers.”

Georg Jaindl, Senior Software Engineer at Vidrio Technologies said, “Vidrio has a pipeline full of exciting new products that we can’t wait to show our customers. By joining forces with MBF, we will be able to build these tools for our customers faster and provide even more responsive technical support than our customers already receive.”

Recent News

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who

01/27/2025

Haleon Expands Richmond Research and Development Facility

Governor Glenn Youngkin announced today that Haleon, a leading global consumer health company, will invest $54.2 million to upgrade its research & development facility in the City of Richmond. The modernization will enable the company to accommodate innovative technologies and expand its research capabilities. Governor Youngkin met with Haleon leadership in London in July 2024